Regeneron Appoints Marketing and Sales Executive and Names Two Other Executives to Strengthen Preclinical and Clinical Development Groups.

Business Editors & Health/Medical Writers

BIOWIRE2K

TARRYTOWN, N.Y.--(BW HealthWire)--March 7, 2002

Senior Management Additions to Promote Product Development

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced three appointments that support the Company's efforts to accelerate the development of new product candidates and bring innovative therapeutic products to market.

Joining the Company are Suzanne Blaug as Vice President of Marketing and Sales; Eric Furfine, Ph.D., as Vice President of Preclinical Development; and Barbara Tardiff, M.D., as Vice President of Clinical Informatics. Ms. Blaug and Dr. Tardiff report to Leonard S. Schleifer, M.D., Ph.D., Regeneron's President and Chief Executive Officer. Dr. Furfine reports to Neil Stahl, Ph.D., Senior Vice President of Preclinical Development and Biomolecular Science.

"Regeneron has an excellent clinical pipeline," noted Dr. Schleifer. "AXOKINE(R) is in a fully enrolled Phase III trial for the treatment of obesity. We recently reported positive preliminary results from our Phase I trial of the IL1 Trap in patients with active rheumatoid arthritis. Late last year, we initiated a Phase I trial for our potent angiogenesis inhibitor, the VEGF Trap, in patients with solid tumor malignancies and non-Hodgkin's lymphoma. Within the next six months, we expect to begin a clinical study of our IL4/13 Trap for asthma and allergies."

Dr. Schleifer continued, "These three executives add skills that we need to fulfill our promise of developing and commercializing important new medicines that can have a significant impact on serious human diseases. Suzanne has broad experience in bringing new products to market and in building and managing the teams required to make those products successful. Barbara's rare combination of expertise in data management technologies plus medical science will strengthen our clinical development team. Eric's capabilities in scientific research and the evaluation and development of therapeutic candidates will help our preclinical group accelerate the analysis of candidate molecules. With these appointments, we significantly strengthen our ability to take product candidates from the lab bench through clinical trials and beyond."

Ms. Blaug, who joins Regeneron from Bristol-Myers Squibb, brings more than 15 years of pharmaceutical industry experience. She has expertise in developing and implementing global strategies for commercialization of major pharmaceutical products, as well as managing regional marketing and sales teams in New Zealand, Australia, and the United Kingdom. Most recently, she was Vice President and Brand Champion for the Worldwide Medicines Group within Bristol-Myers Squibb. A graduate of the University of North Carolina at Chapel Hill, Ms. Blaug received an M.B.A., Marketing and Finance from the Kellogg Graduate School of Business at Northwestern University and attended the General Management Program at the Centre European d'Education Permanente (CEDEP) in Fontainebleau, France.

Dr. Furfine joins Regeneron from GlaxoSmithKline, where he led the department of Biochemical and Analytical Pharmacology. In this role, he guided a multi-disciplinary group that helped accelerate the movement of product candidates from research into development programs. Dr. Furfine was responsible for the pharmacological evaluation of preclinical candidates and was deputy project leader for the next-generation HIV protease inhibitor program. He was also an inventor and the original project leader for fosamprenavir, an HIV protease inhibitor in late stage Phase III clinical trials for GlaxoSmithKline. A high honors graduate in Chemistry at Washington University in St. Louis, he received his Ph.D. in Biochemistry from Brandeis University. Dr. Furfine also conducted post-doctoral research at the University of California, San Francisco.

Dr. Tardiff brings to Regeneron 8 years of experience in pharmaceutical development and 14 years of experience in medical practice and teaching. Most recently she was Vice President of Biomedical Informatics at iBiomatics LLC, a SAS Company, and Assistant Consulting Professor of Anesthesiology at Duke University. Dr. Tardiff has participated in a broad range of clinical research activities, including protocol design, project leadership and administration, data management and information systems, and the presentation of clinical study findings. After graduating from Oregon State University with a degree in Biochemistry and Biophysics, Dr. Tardiff received an M.D. and M.S./M.Phil. in Biology (Molecular Genetics) from Yale University, did graduate work in Applied Information Management at the University of Oregon, and received an M.B.A. from Duke University Fuqua School of Business. She completed a clinical research fellowship at the Duke Clinical Research Institute. Dr. Tardiff is currently a member of the Duke Clinical Research Institute faculty and an Assistant Consulting Professor at Duke University.

About Regeneron

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of obesity, rheumatoid arthritis and cancer and has preclinical programs in asthma, allergies, and other diseases and disorders. Regeneron's platform technologies include Targeted Genomics(TM), Functionomics(TM), and Designer Protein Therapeutics(TM).

This news release discusses historical information and includes forward-looking statements about Regeneron and about its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of drugs and biologics, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement to be canceled or to terminate without any product success, and other material risks. A more complete description of these risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its current Form 10-Q and its Form 10-K for the year ended December 31, 2000. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.

Additional information about Regeneron and recent news releases are available on the Company's web site at www.regn.com. Fax copies of news releases can be obtained from Regeneron's News-on-Demand Service by dialing [phone].